FUSION – BD In Silico Biomarker Discover 2018-12-21T21:17:51+00:00

Call Us Today 888-789-2197  EXT 1

Request Test Drive

Call Us Today 888-789-2197 EXT 1

REQUEST A TEST DRIVE

The Future of Biomarker Research

FUSION BD™ is a feature-rich software application for biomarker discovery utilizing a broad range of multiscale biochemical data and advanced machine learning technologies. FUSION BD allows researchers to identify clinical and molecular signatures of pathogenic processes and disease progression for new drug development and companion diagnostics, to support clinical trial monitoring, and for improved post-marketing safety assessment. FUSION BD is a complete solution providing clinical and experimental data, biochemical knowledge, and automated model development in one integrated system. FUSION BD can be live linked with NGS technologies, high-complexity assays, and digital instrumentation for real-time analysis and process characterization. FUSION BD is accelerating biomarker discovery in support of precision medicine and next generation clinical care.

Molecular Intelligence. Precision Models. Accelerated Research.

FUSION can be utilized across a range of clinical and biochemical disciplines to automatically model and characterize normal and pathogenic processes.

VIEW THESE VIDEOS FROM NIH ON THE FUTURE OF CANCER RESEARCH

FUSION BD IN ACTION

Automating Cancer Research

patient_network
A top-50 university utilizes FUSION BD for automated mining of cancer data sets from TCGA and internally generated experiments. Researchers are testing new molecular signatures to better characterize early-stage tumors and to develop higher-fidelity models of disease progression. From FUSION BD setup to effective discovery in under 10 days.

Advanced Data Set Development

FUSION BD is designed to mine complex multiscale datasets to identify clinical and molecular phenotypes critical to biomarker discovery and drug development. FUSION BD allows researchers to rapidly import and build model training sets utilizing a broad range of data types from clinical, genetic, biochemical, and imaging sources. Users can interactively review this diverse range of data for domain-of-applicability across patient demographics, histopathology, biochemical assays, omic data, and a growing inventory of therapeutic options. Users can further ensure the latest experimental results are utilized during model development through built-in literature search options which access over 20 million peer-reviewed articles automatically filtered on the terms and concepts in your data. FUSION BD is accelerating how quickly high-quality data can be located and utilized in the research enterprise.

Fully integrated clinical and molecular data, pathway knowledge, and disease associations for immediate use in advanced biomarker research.

Automated Biomarker Discovery

biomarker-pheotypesFUSION BD is designed to mine complex multiscale datasets to identify clinical and molecular phenotypes critical to biomarker discovery and drug development. FUSION BD can explore biochemical processes utilizing AI-based search techniques to simultaneously evaluate a broad range of candidate signatures for predictive value across multiple clinical parameters, high-complexity assays, and clinical endpoints. Onscreen automation options allow researchers to control exploration constraints including disease categories, patient demographics and histopathology, therapeutic schedules, standard and emerging assay types, and clinical outcomes. FUSION BD will automatically design and evaluate candidate signature-endpoint combinations based on desired performance specifications. Discovery reporting includes multivariate assessment of process characteristics, pathway involvement, and disease associations.  FUSION BD can identify promising biomarker signatures and perform in silico patient screening without custom programming or costly IT support. FUSION BD is redefining how quickly clinical and molecular signatures can be identified, tested, and deployed in the research enterprise.

FUSION BD models are based on a rich matrix  of chemical and biological features to increase mechanistic interpretability.

Real-Time Biomarker Testing

Biomarkers are used to measure and evaluate normal biological processes, pathogenic events, and pharmacologic response to a therapeutic intervention. With FUSION BD, researchers can now effectively evaluate the predictive value of a biomarker signature for monitoring efficacy and reduced toxicity at the individual patient level. Upon manual or automated submission of patient-state parameters the system will generate and display a process or endpoint prediction, prediction confidence, and a multiscale visual inventory of patient descriptors, molecular interactions, pathway involvement, and disease associations. On-demand access to this diverse range of information assists with both mechanistic understanding and the characterization of clinical utility during companion biomarker development. FUSION BD is redefining the pace and potential of high-complexity biomarkers to accelerate drug development and support the design of more effective and personalized therapy selection strategies at the point-of-care.


  • Comprehensive Biochemical Profiling

  • Real-Time Patient Stratification

  • Weight-of-Evidence Reporting

FUSION BD models can serve as standalone instruments or as embedded microservices within your enterprise discovery platform.

Call Us Today 888-789-2197 EXT 1

Request Test Drive